DOCSLIB.ORG

Constipation and Haemorrhoid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Constipation and Haemorrhoid Pharmacology of Drugs Used in GI Disorders Dr Loh Poh Yen 2 November 2019 Advances in Gastroenterogy • IBD • Biologics eg infliximab, adalimumab • Viral hepatitis B • Antiviral eg Tenofovir alafenamide (Vemlidy) with low resistance rate and good safety profile • Viral hepatitis C • From interferon with lots of side effects and poor response rate to direct acting antivirals with high cure rates 2 How about in general gastroenterology? • Vomiting • Diarrhea • Abdominal pain/ cramp • Liver inflammation (non viral hepatitis cause) 3 vomiting 4 Vomiting pathways 5 • five principle neurotransmitter receptors • muscarinic M1 • dopamine D2 • histamine H1 • 5-hydroxytryptamine (HT)-3 serotonin • neurokinin 1 (NK1) substance P 6 • Muscarinic M1 receptor antagonist • Scopolamine (hyoscine hydrobromide) • predominantly used to treat motion sickness • Side effects include • dry mouth, vision changes, or drowsiness 7 • Dopamine D2 receptor antagonist • Phenothiazines • Butyrophenones • Benzamides 8 • Dopamine D2 receptor antagonist (Phenothiazines) • eg. Prochlorperazine • Side effects include dizziness, headache, dystonia and tardive dyskinesia. • Hypotension can occur in older adults or with intravenous infusion 9 • Dopamine D2 receptor antagonists (Butyrophenones) • eg. Haloperidol • can cause dose-dependent QT prolongation • the need for this class of agents and their utilization has declined 10 • Dopamine D2 receptor antagonists (Benzamides) • eg. Metoclopramide • can cause anxiety, dystonia, tardive dyskinesia, and akathisia domperidone penetrates the blood-brain barrier poorly. Has less common side effects than with metoclopramide 11 • Antihistamines (H1 receptor) • eg. Diphenhydramine, promethazine • primarily used for motion sickness and in pregnancy • Side effects: • Sedation • anticholinergic eg dry mouth, dilated pupils, blurred vision, reduced bowel sounds, and urinary retention 12 • Serotonin-receptor antagonists (5 HT-3 receptor) • eg. Ondansetron • Side effects include • Headache (15 to 20 % of patients) • constipation • QT-prolongation • Serotonin syndrome • when used in conjunction with SSRIs, SNRIs, mirtazapine, monoamine oxidase inhibitors(MAOIs) 13 Current available anti-emetic drugs remarks Dopamine D2 prochlorperazine Extrapyrimidal side effects (phenothiazine) Hypotension with IV infusion Dopamine D2 metoclopramide Extrapyrimidal side effects (Benzamides) Histamine H1 Promethazine, Drowsiness Diphenhydramine Anticholinergic side effects 5 HT-3 Ondansetron Headache avoid in patients with prolonged QTc 14 Use of anti-emetic Situation Associated Recommended antiemetic neurotransmitters migraine dopamine Metoclopramide or prochlorperazine Vestibular Histamine, acetylcholine Antihistamines Pregnancy induced Unknown Promethazine (first line), serotonin antagonists Gastroenteritis Dopamine, serotonin Dopamine antagonist, serotonin antagonist 15 diarrhea 16 adsorbent Antimotility agent Antisecretary agent 17 Antidiarrheal class Mechenism of action Adsorbents Binding to other Charcoal intraluminal contents Smecta Bismuth subsalicylate Antimotility agents Inhibit peristalsis Diphenoxylate-atropine loperamide Antisecretary Inhibit the secretion of racecadotril water and electrolytes into Bismuth subsalicylate the intestines 18 • Smecta • Removes toxins and germs • Mucosa coating (mucosal protection and repair) • 6 sachets/day at the beginning, followed by 3 sachets/day as symptoms improve 19 • Opioid Agonist • activates opioid receptors in the enteric nervous system & decrease peristalsis • Available options • Diphenoxylate + atropine (Lomotil) • Loperamide (Imodium) • Side effect: constipation 20 • Diphenoxylate + Atropine (Lomotil) • diphenoxylate crosses the BBB and produces central effects • higher doses do have euphoric CNS effects & prolonged use can lead to opioid dependence. • Loperamide • does not cross the blood-brain barrier, hence no analgesic or addictive properties 21 • Bismuth salicylate • less effective than loperamide • potential for salicylate toxicity (especially in those who take aspirin and pregnant women) • two tablets every 30 minutes until the diarrhea resolves or eight doses have been taken 22 • Racecadotril (hydrasec) • inhibit breakdown of enkephalin (antisecretary peptide) • begins to work within 30minutes • Can be used in paed and adult • Adult dose: 100mg 8 hourly Weight <9kg 9-13kg 13-27kg >27kg (kg) Dose 10mg 20mg 30mg 60mg (mg tds) Sachet/ 1x10mg 2x10mg 1x30mg 2x30mg dose sachet sachets sachet tds sachets tds tds tds 23 Racecadotril vs loperamide in adult • resolution of symptoms occurred with similar speed and efficacy • racecadotril was associated with less rebound constipation and less abdominal discomfort Wolfgang Fischbach Frontiers Medicine October 2016 24 Current anti-diarrhea treatment Antidiarrheal class remarks Adsorbents Charcoal Smecta Bismuth subsalicylate Beware salicylate toxicity Antimotility agents Diphenoxylate-atropine constipation loperamide Antisecretary racecadotril Adult form not available Bismuth subsalicylate Beware salicylate toxicity 25 Abdominal pain/ cramp 26 Antispasmodic • Actions • Antimuscarinics/ anticholinergics • eg. Hyoscine butylbromide • Smooth muscle relaxants • eg. Alverine, mebeverine, peppermint oil 27 Antispasmodic • Buscopan • Mebeverine • Meteospasmyl • Trimebutine • Librax • Etc No study to suggest one is superior than the other More drugs, more effective to control pain? 28 Descending pain inhibitory pathway Antidepressant eg. TCA, SSRI/SNRI 29 30 • Choice of abdominal pain treatment according to the dominant bowel symptom Constipation diarrhea lubiprostone antispasmodics linaclotide TCA antispasmodics SSRI/SNRI SSRI/SNRI 31 Liver inflammation 32 • Treating the underlying cause is the primary goal in managing liver disease 33 • Non alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are common lifestyle diseases • No safe and effective treatment for NAFLD yet Drug Rx vs placebo Side effect Vitamin E 43% vs 19% Increased overall mortality, hemorrhagic stroke, prostate cancer pioglitazone 34% vs 19% Weight gain, bone fractures, congestive heart failure Liraglutide 39% vs 9% GI side effects Obeticholic acid 45% vs 21% Pruritus, increased LDL 34 Liver supplements/ CAM type examples dose S-adenosylmethionine heptral 1-2 tabs/ day (SAMe) Essential phospholipids Essentiale forte N 2 caps 3 times per day (EPL) (1800mg/d) maintenance: 1 cap 3 times per day (900mg/d) Silymarin Legalon 420mg/d maintenance 280mg/d 35 S-adenosylmethionine (SAMe) • Amino acid derivative of methionine • SAMe synthesis is depressed in chronic liver disease • functions: • methyl donor (cellular function and structure) • synthesis of glutathione (antioxidant) • synthesis of polyamine (liver cell regeneration) 36 Essential phospholipids (EPL) • highly purified extract of polyenylphosphatidylcholine molecules (PPC) from soybean • Functions • Repair and regenerate damaged liver cell membranes • help membrane-dependent cellular functions • antioxidative, and antifibrotic effects 37 Silymarin • active ingredient extracted from Silybium marianum (milk thistle) • Functions • Protect the liver from oxidative stress and sustained inflammatory processes • the supplement is poorly absorbed, and content of preparations is highly variable 38 Evidence of liver supplements • some positive controlled studies • Limited by heterogeneity of studies • many were small, observational studies with significant design flaws • Different doses used in studies • vary considerably in trial duration 39 40 Alcoholic liver disease • SAMe • may improve survival or delay liver transplantation in patients with alcoholic liver cirrhosis, especially in those with less advanced liver disease (child A/B) Mato J Hepatol 1999 • Cochrane 2001 review • No benefit in mortality, transplantation rate 41 Alcoholic liver disease • EPL • A improving trend of transaminases and bilirubin in subgroups with heavy drinkers Lieber CS Alcohol Clin Exp Res, 2003 42 Alcoholic liver disease • Silymarin • normalization of bilirubin, AST and ALT levels, and also improvement in histology in 36 patients with chronic alcoholic liver disease Feher J [Hungarian]. Orv Hetil 1989 • three-month study 31 of 116 patients with histologically proven alcoholic hepatitis randomized to placebo or silymarin showed no significant differences in serum transaminase activity or histologic fibrosis scores. Trinchet JC [French]. Gastroenterol Clin Biol 1989 43 Non alcoholic fatty liver disease • SAMe • resulted in decrease in TC, TG, ALT and AST levels and improvement in symptoms. Boming L. Chinese Hepatol. 2011 • decreased the degree of ALT, AST levels, TG and TC in NASH, and normalization of liver ultra- sonogram in 12 cases (60%) Lei MA Chinese Hepatol. 2011 44 Non alcoholic fatty liver disease • EPL • improved subjective symptoms, hepatomegaly, ultrasonography, liver enzyme levels, liver function and histopathology. • Small studies Karl-Josef Gundermann Pharmacological reports 2011 • meta-analysis showed the clinical efficacy rate was significant, with 83.5% in the treatment group vs. 41.7% under control, however, EPL did not improve the patients’ histology Hu G Liver, 2005 45 Combination of liver supplements • Silybin + vitamin E + phospholipids • Silybin-vitamin E complex given for 1 year showed an improvement in liver enzymes, insulin resistance, and liver histology of NAFLD Loguercio C Free Radic Biol Med 2012 46 Summary • The evidence of benefit is not sufficiently strong to recommend the use of liver supplements • no evidence for a preventive role against liver damage • they appear to be safe • not a substitute for conventional medical therapy 47.
Load more

Recommended publications
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition
    J Neurogastroenterol Motil, Vol. 24 No. 2 April, 2018 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm17145 JNM Journal of Neurogastroenterology and Motility Review Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition Kyung Ho Song,1,2 Hye-Kyung Jung,3* Hyun Jin Kim,4 Hoon Sup Koo,1 Yong Hwan Kwon,5 Hyun Duk Shin,6 Hyun Chul Lim,7 Jeong Eun Shin,6 Sung Eun Kim,8 Dae Hyeon Cho,9 Jeong Hwan Kim,10 Hyun Jung Kim11; and The Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility 1Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea; 2Konyang University Myunggok Medical Research Institute Daejeon, Korea; 3Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea; 4Department of Internal Medicine, Gyeongsang National University, College of Medicine, Jinju, Korea; 5Department of Internal Medicine, Kyungpook National University, School of Medicine, Daegu, Korea; 6Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea; 7Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea; 8Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea; 9Department of Internal Medicine, Sungkyunkwan University School of Medicine, Changwon, Korea; 10Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea; and 11Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea In 2011, the Korean Society of Neurogastroenterology and Motility (KSNM) published clinical practice guidelines on the management of irritable bowel syndrome (IBS) based on a systematic review of the literature. The KSNM planned to update the clinical practice guidelines to support primary physicians, reduce the socioeconomic burden of IBS, and reflect advances in the pathophysiology and management of IBS.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • A Four-Country Comparison of Healthcare Systems, Implementation
    Neurogastroenterology & Motility Neurogastroenterol Motil (2014) 26, 1368–1385 doi: 10.1111/nmo.12402 REVIEW ARTICLE A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders A report of the Rome Foundation Working Team on cross-cultural, multinational research M. SCHMULSON,* E. CORAZZIARI,† U. C. GHOSHAL,‡ S.-J. MYUNG,§ C. D. GERSON,¶ E. M. M. QUIGLEY,** K.-A. GWEE†† & A. D. SPERBER‡‡ *Laboratorio de Hıgado, Pancreas y Motilidad (HIPAM)-Department of Experimental Medicine, Faculty of Medicine-Universidad Nacional Autonoma de Mexico (UNAM). Hospital General de Mexico, Mexico City, Mexico †Gastroenterologia A, Department of Internal Medicine and Medical Specialties, University La Sapienza, Rome, Italy ‡Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India §Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea ¶Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA **Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA ††Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ‡‡Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Key Messages • This report identified seven key issues related to healthcare provision that may impact how patients with FGIDs are investigated, diagnosed and managed. • Variations in healthcare provision around the world in patients with FGIDs have not been reviewed. • We compared four countries that are geographically and culturally diverse, and exhibit differences in the healthcare coverage provided to their population: Italy, South Korea, India and Mexico. • Since there is a paucity of publications relating to the issues covered in this report, some of the findings are based on the authors’ personal perspectives, press reports and other published sources.
    [Show full text]
  • Racecadotril in the Treatment of Acute Diarrhea in Children
    Eberlin et al. BMC Pediatrics (2018) 18:124 https://doi.org/10.1186/s12887-018-1095-x RESEARCH ARTICLE Open Access Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials Marion Eberlin1, Min Chen2, Tobias Mueck1 and Jan Däbritz3,4* Abstract Background: Racecadotril is a guideline-recommended option for the treatment of acute diarrhea in children but existing guidelines and previous reviews of the field are based on a small fraction of published evidence. Therefore, we have performed a systematic search for randomized controlled trials evaluating racecadotril as add-on or in comparison to other treatments. Methods: A search was performed in PubMed, Scopus and Google Scholar without limits about country of origin or reporting language. A meta-analysis was conducted for the five most frequently used efficacy parameters. Results: We have retrieved 58 trials, from nine countries including six in comparison to placebo, 15 in comparison to various active treatments and 41 as add-on to various standard treatments (some multi-armed studies allowing more than one comparison). Trials used 45 distinct efficacy parameters, most often time to cure, % of cured children after 3 days of treatment, global efficacy and number of stools on second day of treatment. Racecadotril was superior to comparator treatments in outpatients and hospitalized patients with a high degree of consistency as confirmed by meta-analysis for the five most frequently used outcome parameters. For instance, it reduced time to cure from 106.2 h to 78.2 h (mean reduction 28.0 h; P < 0.0001 in 24 studies reporting on this parameter).
    [Show full text]
  • A D O L E S C E N
    92739 285-299 23/05/06 16:27 Page 285 VOLUME 26 २ NUMERO 5 MAI 2006 २ CAHIER 2 ADOLESCENCE La diarrhée du nourrisson. De la toxicose à la gastroentérite aiguë : une vieille histoire २ La diarrhée aiguë : un symptôme piège ? २ Diarrhée aiguë du nourrisson : critères de gravité २ Diarrhée aiguë du jeune enfant : quelle mortalité aujourd’hui en France ? २ Le syndrome hémolytique et urémique : toujours l’avoir à l’esprit २ La diarrhée aiguë en crèche : prévention, éviction २ Vaccination antirotavirus: des développements attendus २ Soluté de réhydratation orale : du concept à la commercialisation २ Les conseils à l’officine २ Faut-il bouder le régime antidiarrhéique ? २ Les médicaments antidiarrhéiques २ Antibiotiques et diarrhée aiguë en zone tempérée २ Diarrhée du retour : une entité spécifique ? २ Une campagne régionale d’information et d’éducation des familles २ Doit-on actualiser nos recommandations ? e ISSN 0291-0233 Compte rendu de la 4 Journée du groupe de pédiatrie générale de la Société française de pédiatrie. 92739 285-299 19/05/06 18:57 Page 286 Cahier 2, volume 26, numéro 5, de Médecine & enfance, revue mensuelle répertoriée dans la banque de données CNRS/PASCAL de l’INIST, éditée par Edition et communication médicales, membre du Syndicat national de la presse médicale et des professions de santé. SARL au capital de 7622,45 euros. 23, rue Saint-Ferdinand, 75017 Paris. Tél. : 01.45.74.44.65. Fax : 01.40.55.94.13. RC Paris B 321 539 447. Revue hors commerce, réservée exclusivement au corps médical. Copyright Edition et communication médicales 2006.
    [Show full text]
  • 1This Action Arises Under the Patent Laws of the United States. See 35 U.S.C
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA MCNEIL-PPC, INC., : Plaintiff, : CIVIL ACTION : v. : : L. PERRIGO COMPANY, : and PERRIGO COMPANY, : No. 01-1100 Defendants. : OPINION AND ORDER SCHILLER, J. June , 2002 This is a patent infringement action. Plaintiff McNeil-PPC, Inc. (“McNeil”) alleges Defendants L. Perrigo Company and Perrigo Company (collectively “Perrigo”) infringe four McNeil patents covering a popular version of the Imodium® Advanced antidiarrheal. In a Memorandum and Order issued April 3, 2002, I construed certain disputed claim terms pursuant to Markman v. Westview Instruments, Inc. , 517 U.S. 370 (1996). Beginning April 22, 2002, this matter was tried without a jury, and I enter the following Findings of Fact and Conclusions of Law as required by Rule 52(a) of the Federal Rules of Civil Procedure. 1 FINDINGS OF FACT I. BACKGROUND This action pits a manufacturer of national brand pharmaceuticals against its competitor, a generic drug manufacturer. Four patents owned by Plaintiff McNeil are at issue in this case: United States Patents 5,248,505 (“the ’505 patent”)(PTX1) and 5,612,054 (“the ’054 patent”)(PTX2) are 1This action arises under the patent laws of the United States. See 35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355(j). Jurisdiction is based on 28 U.S.C. §§ 1331 and 1338(a). Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(c) and 1400(b). referred to as “the Garwin patents”; 2 United States Patents 5,679,376 (“the ’376 patent”)(PTX3) and 5,716,641 (“the ’641 patent”)(PTX4) are referred to as “the Stevens patents.” A.
    [Show full text]
  • World Journal of Pharmaceutical Research Yashasvi Et Al
    World Journal of Pharmaceutical Research Yashasvi et al . World Journal of Pharmaceutical SJIF Research Impact Factor 6.805 Volume 6, Issue 1, 998-1004. Research Article ISSN 2277– 7105 EFFICACY OF RACECADOTRIL COMPARED TO DIPHENOXYLATE IN ACUTE RADIATION ENTERITIS Dr. Yashasvi Suvarna*, Dr. Janaki M. G. and Dr. M. C. Shivamurthy Departments of Pharmacology and Radiation Oncology, M S Ramaiah Medical College and Hospitals, Bangalore. ABSTRACT Article Received on 08 Nov. 2016, Introduction: Radiation enteritis is one of the most common and Revised on 28 Nov. 2016, distressing complications of pelvic radiation. There are limited studies Accepted on 18 Dec. 2016 DOI: 10.20959/wjpr20171-7629 that have assessed the efficacy of antidiarrhoeals in radiation enteritis. This study was done to assess the efficacy of racecadotril versus diphenoxylate in acute radiation enteritis. Methods: This was a *Corresponding Author Dr. Yashasvi Suvarna prospective open label randomized study.50 patients were recruited Departments of into the study with 25 patients in each group. They received either Tab. Pharmacology and Racecadotril 100mg tid for 3 days or Tab. Diphenoxylate Radiation Oncology, M S Hydrochloride 2.5 mg(+ atropine 0.025 mg) tid for 3 days as an add on Ramaiah Medical College and Hospitals, Bangalore. to fluid supplementation. Results: The grade of radiation enteritis in both the groups were similar after 3 days of treatment with the drug (p=0.210).Only one patient in the racecadotril group required cessation of pelvic radiation due to hypokalemia. Conclusion: Racecadotril and diphenoxylate are both effective in treating radiation enteritis and are well tolerated. Further studies with racecadotril are warranted.
    [Show full text]
  • The Private Sector Market for Diarrhea Treatment in India
    The Private Sector Market for Diarrhea Treatment in India April 2012 Clinton Health Access Initiative New Delhi, India Table of Contents Abbreviations ..........................................................................................................................................................................3 Acknowledgments..................................................................................................................................................................4 Executive Summary ..............................................................................................................................................................5 Context .......................................................................................................................................................................................8 Methodology ............................................................................................................................................................................9 Diarrhea Treatment Private Sector Supply Chain.................................................................................................... 11 Regulatory Environment .................................................................................................................................................. 16 Manufacturing .....................................................................................................................................................................
    [Show full text]